New shot aims to shield celiac patients from gluten damage
NCT ID NCT06807463
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests an injectable drug called TEV-53408 in 50 adults with celiac disease who follow a gluten-free diet. Participants will be exposed to small amounts of gluten to see if the drug can prevent intestinal damage. The trial is placebo-controlled and lasts about 86 weeks, focusing on safety and how well the drug protects the gut lining.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TEV-53408 (injectable drug)
What this could lead to
If it works, this could point toward a treatment that helps people with celiac disease tolerate accidental gluten exposure without gut damage.
What could go wrong
This is an early Phase 2a trial with only 50 people. It may not show enough benefit or could have side effects. Success in this small study does not guarantee a future approved treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Teva Investigational Site 12121
Wyoming, Michigan, 49519, United States
-
Teva Investigational Site 12122
Ogden, Utah, 84405, United States
-
Teva Investigational Site 12123
Lynchburg, Virginia, 24502, United States
-
Teva Investigational Site 12125
Greenville, North Carolina, 27834, United States
-
Teva Investigational Site 12126
Miami Lakes, Florida, 33016, United States
-
Teva Investigational Site 12127
Winston-Salem, North Carolina, 27103, United States
-
Teva Investigational Site 12128
New York, New York, 10032, United States
-
Teva Investigational Site 12129
Rochester, Minnesota, 55905, United States
-
Teva Investigational Site 12130
Atlanta, Georgia, 30328, United States
-
Teva Investigational Site 12131
Colorado Springs, Colorado, 80907, United States
-
Teva Investigational Site 12132
Clinton Township, Michigan, 48038, United States
-
Teva Investigational Site 12133
Marrero, Louisiana, 70072, United States
-
Teva Investigational Site 12134
Inverness, Florida, 34452, United States
-
Teva Investigational Site 12135
New Port Richey, Florida, 34653, United States
-
Teva Investigational Site 12137
Waco, Texas, 76712, United States
-
Teva Investigational Site 12138
Murrieta, California, 92563, United States
-
Teva Investigational Site 40062
Tampere, 33520, Finland
-
Teva Investigational Site 40063
Helsinki, 00180, Finland
-
Teva Investigational Site 78137
Midland, 6056, Australia
-
Teva Investigational Site 78139
Fitzroy, 3065, Australia
-
Teva Investigational Site 78140
Maroochydore, 4558, Australia